Pci Biotech Holding Stock Target Price
| PCIB Stock | NOK 1.90 0.58 43.94% |
PCI Biotech Holding fundamentals help investors to digest information that contributes to PCI Biotech's financial success or failures. It also enables traders to predict the movement of PCI Stock. The fundamental analysis module provides a way to measure PCI Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PCI Biotech stock.
PCI |
PCI Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PCI Biotech's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PCI Biotech could also be used in its relative valuation, which is a method of valuing PCI Biotech by comparing valuation metrics of similar companies.PCI Biotech is currently under evaluation in target price category among its peers.
PCI Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (15.29) % | |||
| Current Valuation | 25.47 M | |||
| Shares Outstanding | 37.33 M | |||
| Shares Owned By Insiders | 31.97 % | |||
| Shares Owned By Institutions | 6.90 % | |||
| Price To Earning | (10.88) X | |||
| Price To Book | 1.44 X | |||
| Price To Sales | 18.74 X | |||
| Revenue | 6.27 M | |||
| Gross Profit | 6.27 M | |||
| EBITDA | (85.76 M) | |||
| Net Income | (88.39 M) | |||
| Cash And Equivalents | 116.12 M | |||
| Cash Per Share | 8.83 X | |||
| Total Debt | 1.28 M | |||
| Debt To Equity | 0.50 % | |||
| Current Ratio | 16.24 X | |||
| Book Value Per Share | 1.70 X | |||
| Cash Flow From Operations | (68.31 M) | |||
| Earnings Per Share | (2.35) X | |||
| Target Price | 24.0 | |||
| Number Of Employees | 14 | |||
| Beta | 1.86 | |||
| Market Capitalization | 81.93 M | |||
| Total Asset | 135.98 M | |||
| Working Capital | 38 M | |||
| Current Asset | 48 M | |||
| Current Liabilities | 10 M | |||
| Z Score | 38.4 | |||
| Net Asset | 135.98 M |
About PCI Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PCI Biotech Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PCI Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PCI Biotech Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in PCI Stock
PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.